Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors-Reference-Cited by-同舟云学术

Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors

Published:2020-03-03 Issue:5 Volume:19 Page:1210-1217
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Strickler John H.^ORCID,LoRusso Patricia,Salgia Ravi,Kang Yoon-Koo,Yen Chia Jui,Lin Chia-Chi,Ansell Peter,Motwani Monica,Wong Shekman,Yue Huibin,Wang Lan,Reilly Edward^ORCID,Afar Daniel,Naumovski Louie,Ramanathan Ramesh K.

Funder

AbbVie Inc.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells;Molecular Cancer Therapeutics;2024-04-26

2. Exploring marine-derived compounds for MET signalling pathway inhibition in cancer: integrating virtual screening, ADME profiling and molecular dynamics investigations;SAR and QSAR in Environmental Research;2023-11-28

3. MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing;Drugs and Drug Candidates;2023-07-18

4. Investigative algorithms for disorders affecting plasma proteins with a focus on albumin and the calculated globulin fraction: a narrative review;Journal of Laboratory and Precision Medicine;2023-07

5. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review;Molecular Diagnosis & Therapy;2022-03